---
title: "Newly Reported Chronic Hepatitis C Among Adults — Alaska, 2016–2023"
title_zh: "美国阿拉斯加成年人新报告慢性丙型肝炎监测（2016—2023）"
source: "CDC MMWR（Morbidity and Mortality Weekly Report）"
author: "Heather M. Scobie 等（美国疾控中心与阿拉斯加州卫生部）"
date: 2025-03-27
url: "https://www.cdc.gov/mmwr/volumes/74/wr/mm7410a1.htm"
type: 期刊摘要与引言
level: 四六级+
word_count: 1259
tags:
  - 英语阅读/健康与医学
  - 主题/健康与医学
  - 来源/CDC
  - 体裁/期刊摘要与引言
reading_time: 7
related:
  - "[[02-01-身体活动与久坐行为的健康影响]]"
  - "[[02-03-洞穴组织胞浆菌病暴发]]"
  - "[[02-04-疫情封锁中的青少年心理健康]]"
---

# Newly Reported Chronic Hepatitis C Among Adults — Alaska, 2016–2023

> [!note] 本篇导读
> 这是美国疾控中心《发病率和死亡率周报》（MMWR）的一篇流行病学监测报告，主题是阿拉斯加 2016—2023 年成年人慢性丙型肝炎的流行趋势。
> 全文按"摘要—引言—方法—结果—讨论—局限性—公共卫生启示"的标准结构展开，是学习学术英语语篇组织的最佳范本。
> 难度为四六级+：句式并不复杂，但统计术语（率、置信区间、年龄标化）比较密集，建议先读摘要和讨论，再回头看方法。

## 一、英文正文

### Abstract

Hepatitis C virus is a leading cause of chronic liver disease, hepatocellular carcinoma, and liver-related death and is targeted for global elimination as a public health threat by 2030. Universal screening is recommended for all adults aged ≥18 years and pregnant women during each pregnancy; periodic risk-based screening also is recommended. Persons with current infection should be linked to antiviral treatment, which usually results in a virologic cure within 8–12 weeks. To assess progress toward elimination, epidemiologic trends in newly reported chronic hepatitis C cases were assessed among adult Alaska residents during 2016–2023. Overall, 5,352 confirmed chronic hepatitis C cases were newly reported among adults aged ≥18 years. The average annual rate (cases per 100,000 population) was 121 and decreased a relative 30% from 142 during 2016–2019 to 99 during 2020–2023. Statistically significant decreases occurred for most groups. Groups with higher average rates included males, adults aged 18–39 years, residents of rural areas, and American Indian or Alaska Native persons. Hepatitis C surveillance can help monitor trends in health outcomes and identify groups needing tailored testing and treatment interventions toward hepatitis C elimination.

### Introduction

Hepatitis C virus (HCV) is a leading cause of chronic liver disease, hepatocellular carcinoma, and liver-related death and is targeted for elimination as a public health threat by 2030 (_1_). In the United States, an estimated 2.2 million adults had current HCV infection during 2017–2020 (_1_). Hepatitis C incidence and mortality have disproportionately affected American Indian or Alaska Native persons (_2_). Before 2009, hepatitis C risk was highest among persons born during 1945–1965, but recent increases have occurred among young adults in association with increased injection drug use (_3_,_4_). In 2014, direct-acting antiviral treatments for HCV infection became available that result in >95% virologic cure among persons who complete treatment (_4_,_5_). In 2020, CDC recommended universal hepatitis C screening of all adults aged ≥18 years (at least once during their lifetime) and pregnant women during each pregnancy, with subsequent linkage to care for those with current infection; periodic risk-based screening also is recommended (_4_). To assess progress toward elimination, trends in newly reported chronic hepatitis C cases were assessed among adult Alaska residents during 2016–2023.

### Methods

Trends in chronic hepatitis C cases among Alaska residents aged ≥18 years during 2016–2023 were analyzed using data from the National Electronic Disease Surveillance System Base System reported to the Alaska Department of Health as of May 21, 2024. A confirmed case of chronic hepatitis C was defined as 1) a positive test result for HCV RNA, 2) no documentation of converting from negative to positive anti-HCV antibody or HCV RNA test results within the previous 12 months, and 3) not meeting the criteria for or having no report of clinical signs or symptoms of acute hepatitis (i.e., jaundice, total bilirubin ≥3 mg/dL, or serum alanine aminotransferase >200 IU/L).

The numbers and percentage of newly reported chronic hepatitis C cases were analyzed by sex, age group, residential area (urban, rural, and remote), public health region, race, ethnicity, and year that the first positive test result for HCV RNA or antibody was reported.

[...]

### Results

During 2016–2023, a total of 5,352 confirmed cases of chronic hepatitis C among adults aged ≥18 years were newly reported in Alaska. A majority of the cases were among males (66%) and adults aged <40 years (61%). Overall, 25% of cases were reported among women of reproductive age (18–44 years). Median age of newly reported cases was 38 (IQR = 29–54) years in 2016 and 35 (IQR = 30–45) years in 2023.

During 2016–2023, the average annual age-standardized rate of newly reported chronic hepatitis C cases in Alaska was 121 per 100,000 adults. By age group, rates were highest among adults aged 30–39 years (196) and 18–29 years (160) and lowest among those aged ≥60 years (60). By location, rates were highest among adults living in rural areas (162) and among residents of Alaska's Southeast (156), Gulf Coast (154), and Matanuska-Susitna (153) regions. Average rates by race were highest among American Indian or Alaska Native adults (223).

The rate of newly reported chronic hepatitis C per 100,000 adults decreased a relative 30% (95% CI = 26%–35%) from 142 during 2016–2019 to 99 during 2020–2023. From 2016–2019 to 2020–2023, a statistically significant decrease in chronic hepatitis C rates occurred among all age groups except among persons aged 40–49 years. A significant decrease occurred in all regions except the Southwest and Northern regions. A decrease in the chronic hepatitis C rate occurred among American Indian or Alaska Native (−20%), Asian (−45%), White (−26%), and non-Hispanic or Latino persons (−25%). No group experienced a significant increase in chronic hepatitis C.

### Discussion

During 2016–2023, the average annual rate of newly reported chronic hepatitis C in Alaska was 121 cases per 100,000 adults. The overall rate decreased by 30% from 2016–2019 to 2020–2023, similar to national trends. Similar to previous reports, groups with higher newly reported chronic hepatitis C rates included males, adults aged 18–39 years, American Indian or Alaska Native persons, and residents of rural areas.

Rates of newly reported chronic hepatitis C among Alaska adults aged <40 years during the surveillance period were approximately double the national rates reported during 2018 (_3_) and during 2019–2022. Reported rates in Alaska by age group, region, and race might reflect differences in testing related to health care access or use.

Reasons for the decrease in newly reported chronic hepatitis C cases are likely multifactorial, including expanded hepatitis C screening and treatment and changes in health care–seeking, testing practices, or other behaviors, e.g., related to injection drug use or the COVID-19 pandemic. In 2020, national recommendations were expanded to include hepatitis C testing for all adults (_4_). During 2021–2023, increases in opiate-related deaths occurred relative to previous years, and shifts in opioid use from injection to smoking were noted (_8_); both of these factors might have contributed to reduced HCV transmission. Through the efforts of multiple partners in Alaska, hepatitis C screening and treatment has been expanded, including provision of direct-acting antiviral treatment through Medicaid. The impact of these efforts was corroborated in a recent analysis of data from a large commercial laboratory that estimated that 34% of persons with chronic hepatitis C in Alaska achieved viral clearance or cure during 2013–2022, similar to the national rate (the national target is ≥58% by 2025) (_9_).

In Alaska and nationally, challenges remain in ensuring that persons with reactive (positive) HCV antibody test results receive confirmatory testing for HCV RNA (current infection) and subsequent linkage to treatment, especially in remote areas. The point-of-care HCV RNA test, which was approved in June 2024, could help complement existing test-and-treat strategies, such as for populations in remote areas without road access and for those who use injection drugs.

State program goals are to expand hepatitis C screening and linkage to care among disproportionately affected groups, monitor progress through the HCV clearance cascade (from testing to treatment and cure), and improve perinatal hepatitis C surveillance and prevention.

### Limitations

The findings in this report are subject to at least four limitations. First, the reported rates are those of cases newly reported to Alaska by providers and laboratories; the data do not distinguish incident (new) from prevalent infection and would include persons who received positive test results before 2016 but still need treatment, and persons with hepatitis C who have not received testing. Second, the number and rate of chronic hepatitis C cases might be underestimated because only confirmed cases are included. Third, some acute hepatitis C cases might have been misclassified as chronic cases because of missing clinical information and limited reporting of negative HCV RNA test results. Finally, the small size of some demographic groups and changes in the completeness of race and ethnicity data over time likely limited the ability to assess changes in some rates.

### Implications for Public Health Practice

Hepatitis C surveillance can help monitor health outcomes and identify groups needing tailored testing and treatment interventions aimed toward hepatitis C elimination. Further research is needed to better understand factors that contribute to HCV transmission (e.g., differences in access to testing and treatment); additional efforts are needed to improve access to hepatitis C prevention, testing, and treatment services.

---

## 二、生词与短语精讲

> [!tip] 用法
> 先通读正文，再回来核对。建议先遮住中文释义自测。

| 单词/短语 | 音标 | 词性 | 英文释义 | 中文释义 | 文中例句 |
| --- | --- | --- | --- | --- | --- |
| hepatocellular carcinoma | /ˌhepətəʊˈseljələ ˌkɑːsɪˈnəʊmə/ | n. | the most common form of primary liver cancer | 肝细胞癌 | Hepatitis C virus is a leading cause of chronic liver disease, hepatocellular carcinoma, and liver-related death [...] |
| elimination | /ɪˌlɪmɪˈneɪʃn/ | n. | the act of completely removing a disease or problem | 消除；消灭 | [...] is targeted for global elimination as a public health threat by 2030. |
| screening | /ˈskriːnɪŋ/ | n. | testing people for a disease before symptoms appear | 筛查 | Universal screening is recommended for all adults aged ≥18 years and pregnant women during each pregnancy [...] |
| virologic | /ˌvaɪrəˈlɒdʒɪk/ | adj. | relating to viruses or the study of viruses | 病毒学的 | [...] antiviral treatment, which usually results in a virologic cure within 8–12 weeks. |
| surveillance | /sɜːˈveɪləns/ | n. | the continuous collection of data to monitor a disease | 监测 | Hepatitis C surveillance can help monitor trends in health outcomes [...] |
| tailored | /ˈteɪləd/ | adj. | designed for a particular person or purpose | 量身定制的 | [...] identify groups needing tailored testing and treatment interventions [...] |
| incidence | /ˈɪnsɪdəns/ | n. | the number of new cases of a disease in a period | 发病率 | Hepatitis C incidence and mortality have disproportionately affected American Indian or Alaska Native persons [...] |
| disproportionately | /ˌdɪsprəˈpɔːʃənətli/ | adv. | to an extent that is too large or too small compared with others | 不成比例地；格外严重地 | Hepatitis C incidence and mortality have disproportionately affected American Indian or Alaska Native persons [...] |
| antiviral | /ˌæntiˈvaɪrəl/ | adj. | used to treat infections caused by viruses | 抗病毒的 | In 2014, direct-acting antiviral treatments for HCV infection became available [...] |
| documentation | /ˌdɒkjumenˈteɪʃn/ | n. | official written records that prove something | 记录；证明文件 | [...] no documentation of converting from negative to positive anti-HCV antibody or HCV RNA test results within the previous 12 months [...] |
| jaundice | /ˈdʒɔːndɪs/ | n. | a condition in which the skin and eyes turn yellow | 黄疸 | [...] clinical signs or symptoms of acute hepatitis (i.e., jaundice, total bilirubin ≥3 mg/dL [...] |
| serum | /ˈsɪərəm/ | n. | the clear liquid part of blood | 血清 | [...] or serum alanine aminotransferase >200 IU/L). |
| median | /ˈmiːdiən/ | n. | the middle value in a set of numbers arranged in order | 中位数 | Median age of newly reported cases was 38 (IQR = 29–54) years in 2016 and 35 (IQR = 30–45) years in 2023. |
| reproductive age | /ˌriːprəˈdʌktɪv eɪdʒ/ | n. | the age range during which a woman can become pregnant | 育龄 | Overall, 25% of cases were reported among women of reproductive age (18–44 years). |
| statistically significant | /stəˈtɪstɪkli sɪɡˈnɪfɪkənt/ | adj. | unlikely to have happened by chance alone | 具有统计学显著性的 | Statistically significant decreases occurred for most groups. |
| multifactorial | /ˌmʌltifækˈtɔːriəl/ | adj. | caused by several different factors | 多因素的 | Reasons for the decrease in newly reported chronic hepatitis C cases are likely multifactorial [...] |
| corroborate | /kəˈrɒbəreɪt/ | v. | to provide evidence that supports a statement or finding | 证实；印证 | The impact of these efforts was corroborated in a recent analysis of data from a large commercial laboratory [...] |
| viral clearance | /ˈvaɪrəl ˈklɪərəns/ | n. | the removal of a virus from the body | 病毒清除 | [...] estimated that 34% of persons with chronic hepatitis C in Alaska achieved viral clearance or cure during 2013–2022 [...] |
| reactive | /riˈæktɪv/ | adj. | showing a positive response in a medical test | 阳性的；有反应的 | [...] ensuring that persons with reactive (positive) HCV antibody test results receive confirmatory testing [...] |
| confirmatory | /kənˈfɜːmətri/ | adj. | serving to prove that an earlier result is correct | 确证的 | [...] receive confirmatory testing for HCV RNA (current infection) and subsequent linkage to treatment [...] |
| point-of-care | /ˌpɔɪnt əv ˈkeə(r)/ | adj. | (of a test) performed where the patient is, rather than in a lab | 床旁检测的；即时检验的 | The point-of-care HCV RNA test, which was approved in June 2024, could help complement existing test-and-treat strategies [...] |
| perinatal | /ˌperiˈneɪtl/ | adj. | relating to the time around birth | 围产期的 | [...] and improve perinatal hepatitis C surveillance and prevention. |
| prevalent | /ˈprevələnt/ | adj. | (of an infection) already present in a population, not newly caught | 现存的；流行的 | [...] the data do not distinguish incident (new) from prevalent infection [...] |

### 高频搭配与短语动词

| 搭配 | 中文 | 例句 |
| --- | --- | --- |
| be targeted for | 被列为……的目标 | [...] is targeted for global elimination as a public health threat by 2030. |
| be linked to | 被转介到；与……相连 | Persons with current infection should be linked to antiviral treatment [...] |
| in association with | 与……相关联 | [...] recent increases have occurred among young adults in association with increased injection drug use [...] |
| be subject to | 受……影响；易受…… | The findings in this report are subject to at least four limitations. |
| result in | 导致；造成 | [...] antiviral treatments for HCV infection became available that result in >95% virologic cure [...] |
| relative to | 相对于 | During 2021–2023, increases in opiate-related deaths occurred relative to previous years [...] |
| contribute to | 促成；有助于 | [...] both of these factors might have contributed to reduced HCV transmission. |
| be recommended for | 被推荐用于…… | Universal screening is recommended for all adults aged ≥18 years [...] |
| in alignment with | 与……保持一致 | [...] is drafting a state plan for viral hepatitis elimination, in alignment with national elimination efforts. |
| be aimed toward | 以……为目标 | [...] identify groups needing tailored testing and treatment interventions aimed toward hepatitis C elimination. |

## 三、长难句解析

> [!example] 长难句 1
> **原句**：In 2020, CDC recommended universal hepatitis C screening of all adults aged ≥18 years (at least once during their lifetime) and pregnant women during each pregnancy, with subsequent linkage to care for those with current infection; periodic risk-based screening also is recommended.（42 词）
> **结构拆解**：全句由分号连接两个并列分句。前一分句主干是 "CDC recommended universal hepatitis C screening"，宾语 screening 后接两个并列的 of 介词短语（of all adults ... and pregnant women ...）；"aged ≥18 years" 是过去分词短语作后置定语修饰 adults；括号内 "at least once during their lifetime" 是插入语，补充说明筛查频率；"with subsequent linkage to care for those with current infection" 是 with 复合结构作补充说明。后一分句是简单的被动语态，表示"也推荐基于风险的定期筛查"。
> **参考翻译**：2020 年，美国疾控中心建议对所有 18 岁及以上成年人（一生中至少一次）以及孕妇在每次妊娠期间进行普遍性丙型肝炎筛查，并为现症感染者提供后续的诊疗转介；此外也建议开展基于风险的定期筛查。
>
> [!example] 长难句 2
> **原句**：A confirmed case of chronic hepatitis C was defined as 1) a positive test result for HCV RNA, 2) no documentation of converting from negative to positive anti-HCV antibody or HCV RNA test results within the previous 12 months, and 3) not meeting the criteria for or having no report of clinical signs or symptoms of acute hepatitis (i.e., jaundice, total bilirubin ≥3 mg/dL, or serum alanine aminotransferase >200 IU/L).（70 词）
> **结构拆解**：主句是被动语态 "A confirmed case ... was defined as"，后面接三个带编号的并列成分（1、2、3），构成 as 的宾语。第 1 项是名词短语；第 2 项的核心名词 documentation 后接 of 加动名词短语 "converting from negative to positive ... within the previous 12 months"；第 3 项是动名词短语 "not meeting the criteria for or having no report of ..."，其中 for 与 of 分别支配两个并列宾语，句末括号内的 i.e. 引出三项实验室指标作为插入解释。
> **参考翻译**：慢性丙型肝炎确诊病例的定义为：1）HCV RNA 检测结果阳性；2）既往 12 个月内没有抗-HCV 抗体或 HCV RNA 检测由阴性转为阳性的记录；3）不符合急性肝炎的临床体征或症状标准，或没有相关报告（即黄疸、总胆红素 ≥3 mg/dL，或血清丙氨酸氨基转移酶 >200 IU/L）。
>
> [!example] 长难句 3
> **原句**：The impact of these efforts was corroborated in a recent analysis of data from a large commercial laboratory that estimated that 34% of persons with chronic hepatitis C in Alaska achieved viral clearance or cure during 2013–2022, similar to the national rate (the national target is ≥58% by 2025).（49 词）
> **结构拆解**：主句主干是被动语态 "The impact ... was corroborated"，"of these efforts" 是后置定语修饰 impact，"in a recent analysis of data from a large commercial laboratory" 是介词短语作状语，交代印证来源。laboratory 后接 that 引导的定语从句 "that estimated that ..."，其中第一个 that 是关系代词作从句主语，第二个 that 引导宾语从句 "34% of persons ... achieved viral clearance or cure"；"similar to the national rate" 是形容词短语作补充说明，句末括号内的内容又追加了全国目标值。
> **参考翻译**：这些努力的效果在一项近期分析中得到印证：该分析使用一家大型商业实验室的数据，估算出 2013—2022 年间阿拉斯加 34% 的慢性丙型肝炎患者实现了病毒清除或治愈，与全国水平相近（全国目标是到 2025 年达到 ≥58%）。

## 四、专业词汇标注

> [!important] 专业词汇
> 这些词只需"认识"，不必会拼写。

| 专业词汇 | 中文解释 | 所属领域 |
| --- | --- | --- |
| HCV (hepatitis C virus) | 丙型肝炎病毒 | 病毒学 |
| HCV RNA | 丙肝病毒核酸（提示现症感染） | 检验医学 |
| anti-HCV antibody | 抗丙肝病毒抗体（提示曾经或正在感染） | 检验医学 |
| direct-acting antiviral (DAA) | 直接抗病毒药物 | 药物治疗 |
| chronic liver disease | 慢性肝病 | 医学 |
| age-standardization | 年龄标化（消除年龄结构差异的统计方法） | 流行病学 |
| 95% CI (confidence interval) | 95% 置信区间 | 统计学 |
| IQR (interquartile range) | 四分位距 | 统计学 |
| alanine aminotransferase (ALT) | 丙氨酸氨基转移酶（肝功能指标） | 检验医学 |
| Medicaid | 美国面向低收入人群的公共医疗保险 | 卫生政策 |
| HCV clearance cascade | 丙肝清除级联（从检测到治愈的连续监测指标） | 公共卫生 |

## 五、阅读训练建议

- [ ] 第一遍：不看注释通读全文，记录用时 ___ 分钟
- [ ] 第二遍：查生词表，回读卡住的句子
- [ ] 第三遍：只看英文，口头复述每段大意
- [ ] 输出：用 5 句英文写出本文摘要

> [!tip] 关联阅读
> - [[02-01-身体活动与久坐行为的健康影响]] —— 同属公共卫生语域，但一篇是建议性事实清单，一篇是数据驱动的监测报告。
> - [[02-03-洞穴组织胞浆菌病暴发]] —— 同为 MMWR 报告，可对比"长期监测"与"急性暴发调查"两种叙事结构。
> - [[02-04-疫情封锁中的青少年心理健康]] —— 参见研究论文如何用统计模型（而非率与置信区间）解释健康结局。

> [!warning] 易混提示
> `incidence`（发病率，只统计新发病例）与 `prevalence`（患病率，包含所有现存病例）在流行病学中不可互换；本文 Limitations 一节正是用这一区别指出数据的局限。

## 六、来源与版权说明

- 原文标题：Newly Reported Chronic Hepatitis C Among Adults — Alaska, 2016–2023
- 来源：CDC, Morbidity and Mortality Weekly Report（MMWR），2025 年 3 月 27 日，74(10);161–166
- 原文链接：https://www.cdc.gov/mmwr/volumes/74/wr/mm7410a1.htm
- 说明：本篇英文正文为原文节选（删节处标 `[...]`），仅用于个人英语学习；版权归原作者与发布机构所有。
